FindTrial
Sign In

Study on the molecular mechanism of hepatotoxicity caused by osimertinib-induced TFEB activation leading to lysosomal homeostasis imbalance

Study on the molecular mechanism of hepatotoxicity caused by osimertinib-induced TFEB activation leading to lysosomal homeostasis imbalance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114479
Enrollment
Unknown
Registered
2025-12-12
Start date
2025-12-31
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver toxicity caused by osimertinib: elevated ALT/AST

Interventions

Observation group:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patient samples with preoperative adjuvant treatment after using osimertinib and elevated ALT/AST, or patient samples with advanced cancer and liver metastasis undergoing biopsy, while collecting the adjacent normal tissue samples from tumor patients with similar tumor stages but without corresponding toxicities as controls. There is no special specification for the type of tumor.

Exclusion criteria

Exclusion criteria: 1.Patients with other unexplained liver or lung damage.

Design outcomes

Primary

MeasureTime frame
The patient developed liver toxicity after taking osimertinib.;—

Countries

China

Contacts

Public ContactYueping Qiu

Zhejiang Cancer Hospital

qiuyp@zjcc.org.cn+86 571 8812 2438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026